Champions Oncology, Inc.
CSBRNASDAQHealthcareBiotechnology
Previous close
$4.9601
−$0.2199 · -4.25%
CSBR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
65
Undervalued
Momentum
32
Weakening
Sentiment
40
Bearish
Risk resilience
38
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteChampions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Robert Brainin
- Listed since
- Feb 2, 2007
- Employees
- 214
Market position
Day range
Current $4.9601
52-week range
Current $4.9601
- Open
- $5.24
- Previous close
- $5.18
- Volume
- 8.11K
- 0.88× average
- Average volume
- 9.18K
- Average daily volume
- Market cap
- 68.91M USD
- Beta
- 0.41
- Market reference 1
- 50-day average
- $5.7822
- -14.22% below average
- 200-day average
- $6.1764
- -19.69% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -62×
- P/B (TTM)
- 17.42×
- P/S (TTM)
- 1.16×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 48.00%
- Operating margin
- -1.92%
- Net margin
- -1.98%
Financial health
- Debt / equity
- 1.17×
- Altman Z-score
- -0.34
- Piotroski F-score
- 3 of 9
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- +342.12%
- 11 comparable reports
- Latest EPS result
- 0.01
- Estimate -0.05 · Beat by 120.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$12.00
141.93% upsideRecent analyst actions
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 12, 2015 | 1:12 | — | — |
Effective Aug 12, 2015
1:12
CSBR peers
ETFs holding CSBR
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 1.23M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 336.47K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Micro-Cap ETFIWC- Market value
- 149.33K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research CSBRresearch.disclaimer